The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mitomycin plus BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: A randomized phase 3 trial (ANZUP 1301).
 
Dickon Hayne
Consulting or Advisory Role - AstraZeneca/Merck
Speakers' Bureau - BMC Neuroscience
Research Funding - AstraZeneca/UK; Telix Pharmaceuticals
 
Alison Zhang
Honoraria - Astellas Pharma; AstraZeneca; Bayer; MSD Oncology; Mundipharma; Pfizer (Inst)
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bayer; Janssen Oncology; Merck; Merck Sharp & Dohme; Pfizer
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; MSD Oncology
 
Hayley Thomas
No Relationships to Disclose
 
Stephen McCombie
Consulting or Advisory Role - MSD
 
Cynthia Hawks
Employment - Solventum (I)
Travel, Accommodations, Expenses - MSD
 
Paul Anderson
No Relationships to Disclose
 
Patricia Bastick
No Relationships to Disclose
 
Emma Beardsley
Consulting or Advisory Role - MSD
Travel, Accommodations, Expenses - MSD
 
William Green
No Relationships to Disclose
 
Mark Frydenberg
No Relationships to Disclose
 
Jeremy Grummet
No Relationships to Disclose
 
Joseph Ischia
No Relationships to Disclose
 
Laurence Krieger
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck; MSD; Novartis
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck; MSD; Novartis
Travel, Accommodations, Expenses - Janssen-Cilag
 
Andrew Mitterdorfer
No Relationships to Disclose
 
Manish Patel
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Janssen
 
Shomik Sengupta
Honoraria - Bristol-Myers Squibb; Janssen Oncology
(OPTIONAL) Uncompensated Relationships - ANZUP Trials Group
 
Ratnesh Srivastav
No Relationships to Disclose
 
Andrew Redfern
Honoraria - Astellas Pharma; AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer
 
Ian Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); ESSA (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.
(OPTIONAL) Uncompensated Relationships - ANZUP Cancer Trials Group
 
Martin Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
 
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
No Relationships to Disclose